Revenue
No reported data
Propanc Biopharma, Inc. (PPCB)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2014
2015
2016
2019
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | $223,721 | $248,102 | $247,919 | $256,052 | $230,956 | $179,987 | $260,335 | $1.8M | $971,769 | $1.4M | $134,319 | $8,168 | $12,344 | $5,279 | $385,777 | — | — |
| Operating expenses | $57.3M | $1.5M | $1.8M | $2.0M | $1.8M | $3.5M | $2.6M | $4.0M | $5.7M | $6.9M | $1.7M | $761,221 | $1.4M | $11.6M | $2.2M | — | — |
| Operating income | −$57.3M | −$1.5M | −$1.8M | −$2.0M | −$1.8M | −$3.5M | −$2.6M | −$4.0M | −$5.7M | −$6.9M | −$1.7M | −$761,221 | −$1.4M | −$11.6M | −$2.2M | — | — |
| EBITDAderived | — | — | — | — | — | — | — | — | — | — | — | — | −$1.4M | −$11.6M | −$2.2M | — | — |
| Net income | −$58.9M | −$1.8M | −$2.7M | −$2.7M | −$2.0M | −$4.7M | −$5.8M | −$7.0M | −$7.9M | −$9.4M | −$3.4M | −$829,564 | −$1.4M | −$11.4M | −$2.2M | −$842,487 | −$443,849 |
| Basic EPSper diluted share | -$14.85 | -$1,420.53 | -$1.80 | -$49.23 | -$0.80 | -$192.45 | -$10.97 | -$178.75 | -$2.24 | -$4.83 | -$0.02 | -$0.01 | -$0.02 | -$0.16 | -$0.03 | — | — |
| Diluted EPSper diluted share | -$14.85 | -$1,420.53 | -$1.80 | -$49.23 | -$0.80 | -$192.45 | -$10.97 | -$178.75 | -$2.24 | -$4.83 | -$0.02 | -$0.01 | -$0.02 | -$0.16 | -$0.03 | — | — |